Check(point)s and balances: ' Know thy enemy'
- PMID: 40042060
- DOI: 10.1097/HEP.0000000000001296
Check(point)s and balances: ' Know thy enemy'
References
-
- Moeckli B, Wassmer CH, El Hajji S, Kumar R, Rodrigues Ribeiro J, Tabrizian P, et al. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study. Hepatology. 2025 Mar 5. doi: 10.1097/HEP.0000000000001289. Epub ahead of print. - DOI
-
- Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
-
- Centanni M, Moes D, Troconiz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58:835–857.
-
- Woo SM, Kimchy AV, Sequeira LM, Dorris CS, He AR, Rangnekar AS. Immunotherapy use prior to liver transplant in patients with hepatocellular carcinoma. Curr Oncol. 2022;29:9813–9825.
-
- Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456.
LinkOut - more resources
Full Text Sources